Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · IEX Real-Time Price · USD
22.05
+0.19 (0.87%)
May 3, 2024, 4:00 PM EDT - Market closed
Syndax Pharmaceuticals Employees
Syndax Pharmaceuticals had 184 employees on December 31, 2023. The number of employees increased by 77 or 71.96% compared to the previous year.
Employees
184
Change (1Y)
77
Growth (1Y)
71.96%
Revenue / Employee
n/a
Profits / Employee
-$1,137,826
Market Cap
1.87B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 184 | 77 | 71.96% |
Dec 31, 2022 | 107 | 48 | 81.36% |
Dec 31, 2021 | 59 | 16 | 37.21% |
Dec 31, 2020 | 43 | 8 | 22.86% |
Dec 31, 2019 | 35 | -3 | -7.89% |
Dec 31, 2018 | 38 | -6 | -13.64% |
Dec 31, 2017 | 44 | 12 | 37.50% |
Dec 31, 2016 | 32 | 16 | 100.00% |
Dec 31, 2015 | 16 | 3 | 23.08% |
Nov 21, 2014 | 13 | 0 | - |
Dec 31, 2013 | 13 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Owens & Minor | 22,200 |
Amneal Pharmaceuticals | 7,700 |
Evotec SE | 4,952 |
Galapagos NV | 1,123 |
Schrödinger | 867 |
Recursion Pharmaceuticals | 500 |
Agios Pharmaceuticals | 386 |
Avadel Pharmaceuticals | 154 |
SNDX News
- 20 hours ago - Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 3 days ago - Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024 - PRNewsWire
- 23 days ago - Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum - PRNewsWire
- 26 days ago - Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session - PRNewsWire
- 4 weeks ago - Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 5 weeks ago - Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia - PRNewsWire
- 5 weeks ago - Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia - PRNewsWire
- 6 weeks ago - Syndax Announces Appointment of Steven Closter as Chief Commercial Officer - PRNewsWire